Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 867399 | ISIN: US9105711082 | Ticker-Symbol:
NASDAQ
23.01.25
15:30 Uhr
10,830 US-Dollar
+0,320
+3,04 %
Branche
Kosmetik
Aktienmarkt
Sonstige
1-Jahres-Chart
UNITED-GUARDIAN INC Chart 1 Jahr
5-Tage-Chart
UNITED-GUARDIAN INC 5-Tage-Chart
GlobeNewswire (Europe)
527 Leser
Artikel bewerten:
(2)

United-Guardian, Inc.: United-Guardian Reports Increased Third Quarter Earnings

Finanznachrichten News

HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30th increased from $8,278,141 in 2023 to $9,705,262 in 2024 and net income increased from $1,843,931 ($0.40 per share) to $2,747,151 ($0.60 per share) for the same period. The third quarter remained steady with sales of $3,057,518 in 2023 and $3,060,113 in 2024, while net income increased from $626,756 ($0.14 per share) to $865,484 ($0.19 per share).

Donna Vigilante, President of United-Guardian, stated, "We are pleased to announce that sales and earnings increased in the third quarter and for the first nine months of 2024 compared with the same periods in 2023. We continue to have strong sales of our cosmetic ingredients, which increased by 8% in the third quarter and 68% in the first nine months of 2024. This overall increase was primarily attributable to sales to our largest cosmetic distributor. Sales of medical lubricants decreased by 2% in the third quarter, which was attributed to normal fluctuation in order patterns, while increasing by 4% in the first nine months of 2024, compared with the same periods in 2023. Pharmaceutical product sales continue to recover from a supply disruption that occurred at our contract manufacturer for Renacidin®, our most important pharmaceutical product, late last year. Sales of pharmaceuticals decreased by 6% in the third quarter and 11% for the nine-month period. We expect our sales will continue to increase as we recover from the shutdown that limited our supply of Renacidin."

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.

Contact: Donna Vigilante
(631) 273-0900
dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

Financial Results for the
Three and Nine Months Ended
September 30, 2024 and 2023

STATEMENTS OF INCOME
(unaudited)
THREE MONTHS ENDED
SEPTEMBER 30,
NINE MONTHS ENDED
SEPTEMBER 30,
2024 2023 2024 2023
Net sales$3,060,113 $3,057,518 $9,705,262 $8,278,141
Costs and expenses:
Cost of sales 1,408,866 1,749,041 4,526,446 4,272,043
Operating expenses 591,047 488,464 1,762,689 1,580,503
Research and development expense 111,072 98,141 325,714 353,829
Total costs and expenses 2,110,985 2,335,646 6,614,849 6,206,375
Income from operations 949,128 721,872 3,090,413 2,071,766
Other Income (expense):
Investment income 99,934 79,682 298,014 182,264
Net gain (loss) on marketable securities 47,223 (14,357) 79,218 65,823
Total other income 147,157 65,325 377,232 248,087
Income before provision for income taxes

1,096,285 787,197 3,467,645 2,319,853
Provision for income taxes 230,801 160,441 720,494 475,922
Net income$ 865,484 $ 626,756 $2,747,151 $1,843,931
Earnings per common share (Basic and Diluted)$0.19 $0.14 $0.60 $ 0.40
Weighted average shares - basic and diluted 4,594,319
4,594,319
4,594,319
4,594,319

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.